

**WEDNESDAY 8<sup>th</sup> FEBRUARY 2012 COMMENCING 10.30 AM**  
**(UNTIL 4.00 PM APPROX)**  
**AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN**

### **AGENDA**

**Enclosure**

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Chairman's report (verbal update)**
5. **Minutes of previous meeting**

1/AWMSG/0212

**Appraisal 1 - 4 will be held in public. Appraisal 5 - 6 form part of the pilot for considering patient access schemes within NHS Wales and will be held in private**

6. **Appraisal 1**  
**Linagliptin (Trajenta<sup>®</sup>)** for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:  
Monotherapy:
  - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.Combination therapy:
  - in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
  - in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control**2/AWMSG/0212**  
**Appendices**
7. **Appraisal 2**  
**Entecavir (Baraclude<sup>®</sup>)** for the treatment of chronic hepatitis B virus infection in adults with decompensated liver disease  
**3/AWMSG/0212**  
**Appendices**
8. **Appraisal 3**  
**Trastuzumab (Herceptin<sup>®</sup>)** for the treatment of patients with HER2-positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel, or the treatment of patients with HER2-positive early breast cancer in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin  
**4/AWMSG/0212**  
**Appendices**

9. **Appraisal 4**  
**Capsaicin patch (Qutenza®)** for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain

5/AWMSG/0212  
**Appendices**

10. **Date of next meeting - Wednesday, 21<sup>st</sup> March 2012 in Cardiff**

**Proceedings held in public will close and the remainder of the meeting will be held in private with representatives of the applicant pharmaceutical company in attendance. The information pertaining to agenda items 10 and 11 will not be posted on the AWMSG website**

10. **Appraisal 5**  
**Icatibant acetate (Firazyr®)** for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency)

6/AWMSG/0212  
**Appendices**

11. **Appraisal 6**  
**Abiraterone (Zytiga®)** in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen

7/AWMSG/0212  
**Appendices**